← Leaderboards
Genoveffa Franchini
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusMacacaInfectionCellsProteinsT-LymphocyteResponseViralCd4 Positive T LymphocytesAffectImmuneMonocyteImmune ResponseVaccinesBloodAntigensMediatingAnimal ModelAnimalsPreventCd8b1 GeneHiv VaccineAntibodiesIn Vivo
Grant awards (46)
Phase I HIV vaccine trial with DNAALVAC-HIV gp120 delta V1 vaccines$7,428,773
ZIA · FY2025 · CA · contact PI
Development of rationally designed HIV vaccines$3,542,953
ZIA · FY2025 · CA · contact PI
Essential Logistic Needs to Implement the C.L.E.A.R. Phase-I HIV Vaccine Trial$880,288
ZIA · FY2025 · CA · contact PI
Role of the HTLV-1A and HTLV1-C inflammatory profile in disease$342,866
ZIA · FY2025 · CA · contact PI
Phase I HIV vaccine trial with DNAALVAC-HIV gp120 delta V1 vaccines$5,494,609
ZIA · FY2024 · CA · contact PI
Development of rationally designed HIV vaccines$2,580,801
ZIA · FY2024 · CA · contact PI
Role of the HTLV-1A and HTLV1-C inflammatory profile in disease$249,755
ZIA · FY2024 · CA · contact PI
Phase I HIV vaccine trial with DNAALVAC-HIV gp120 delta V1 vaccines$4,110,031
ZIA · FY2023 · CA · contact PI
Development of rationally designed HIV vaccines$2,689,105
ZIA · FY2023 · CA · contact PI
Role of the HTLV-1A and HTLV1-C inflammatory profile in disease$166,365
ZIA · FY2023 · CA · contact PI
Phase I HIV vaccine trial with DNAALVAC-HIV gp120 delta V1 vaccines$9,055,951
ZIA · FY2022 · CA · contact PI
Development of rationally designed HIV vaccines$4,253,554
ZIA · FY2022 · CA · contact PI
Role of the HTLV-1A and HTLV1-C inflammatory profile in disease$411,634
ZIA · FY2022 · CA · contact PI
Phase I HIV vaccine trial with DNAALVAC-HIV gp120 delta V1 vaccines$9,534,502
ZIA · FY2021 · CA · contact PI
Development of rationally designed HIV vaccines$4,206,398
ZIA · FY2021 · CA · contact PI
Role of the HTLV-1A and HTLV1-C inflammatory profile in disease$280,426
ZIA · FY2021 · CA · contact PI
Development of rationally designed HIV vaccines$4,395,296
ZIA · FY2020 · CA · contact PI
Role of the HTLV-1A and HTLV1-C inflammatory profile in disease$231,331
ZIA · FY2020 · CA · contact PI
Development of rationally designed HIV vaccines$4,231,061
ZIA · FY2019 · CA · contact PI
Role of the HTLV-1A and HTLV1-C inflammatory profile in disease$222,687
ZIA · FY2019 · CA · contact PI
Preventive Vaccines for HIV$6,398,923
ZIA · FY2018 · CA · contact PI
T-cell Transformation by Oncoviruses$336,785
ZIA · FY2018 · CA · contact PI
Preventive Vaccines for HIV$3,827,071
ZIA · FY2017 · CA · contact PI
T-cell Transformation by Oncoviruses$425,230
ZIA · FY2017 · CA · contact PI
Preventive Vaccines for HIV$3,508,007
ZIA · FY2016 · CA · contact PI
T-cell Transformation by Oncoviruses$389,779
ZIA · FY2016 · CA · contact PI
Preventive Vaccines for HIV$2,446,406
ZIA · FY2015 · CA · contact PI
T-cell Transformation by Oncoviruses$1,317,296
ZIA · FY2015 · CA · contact PI
Preventive Vaccines for HIV$2,684,061
ZIA · FY2014 · CA · contact PI
T-cell Transformation by Oncoviruses$1,445,263
ZIA · FY2014 · CA · contact PI
Preventive Vaccines for HIV$2,673,929
ZIA · FY2013 · CA · contact PI
T-cell Transformation by Oncoviruses$1,439,808
ZIA · FY2013 · CA · contact PI
Preventive Vaccines for HIV$2,289,324
ZIA · FY2012 · CA · contact PI
T-cell Transformation by Oncoviruses$1,780,586
ZIA · FY2012 · CA · contact PI
Understanding the Role of the Host Response in HIVSIV Infection$1,017,478
ZIA · FY2012 · CA · contact PI
Preventive Vaccines for HIV$2,297,148
ZIA · FY2011 · CA · contact PI
T-cell Transformation by Oncoviruses$1,786,670
ZIA · FY2011 · CA · contact PI
Understanding the Role of the Host Response in HIVSIV Infection$1,020,955
ZIA · FY2011 · CA · contact PI
T-cell Transformation by Oncoviruses$1,659,426
ZIA · FY2010 · CA · contact PI
Preventive Vaccines for HIV$1,659,426
ZIA · FY2010 · CA · contact PI
Understanding the Role of the Host Response in HIVSIV Infection$1,422,365
ZIA · FY2010 · CA · contact PI
Preventive Vaccines for HIV$1,571,294
ZIA · FY2009 · CA · contact PI
T-cell Transformation by Oncoviruses$1,571,294
ZIA · FY2009 · CA · contact PI
Understanding the Role of the Host Response in HIVSIV Infection$1,346,823
ZIA · FY2009 · CA · contact PI
Preventive Vaccines for HIV$1,116,963
Z01 · FY2008 · CA · contact PI
Inhibition of Type 1 Interferon During SIV Infection$558,482
Z01 · FY2008 · CA · contact PI